The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.

Dr Erica Schwartz, nominated to lead the US Centers for Disease Control and Prevention, is highly qualified, according to ...

By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.

Gabapentinoids are associated with an increased risk for drug poisoning, particularly in the short-term after initiation, according to a study published online ...

Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...

Adults with IgA nephropathy treated with ravulizumab show significant proteinuria improvement as early as week 10.

Based on positive phase 3 trial results, a New Drug Application will be submitted to the Food and Drug Administration for daraxonrasib.

Older adults with adenoma at prior colonoscopy more likely to experience CRC but risk exceeded by competing risks for non-CRC death.

No increase seen in incidence of major bleeding, adverse events, or serious adverse events compared with placebo.

The US Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies. Peptides are small chains of amino acids ...